All Stories

  1. Impaired myoblast differentiation and muscle IGF‐1 receptor signaling pathway activation after N‐glycosylation inhibition
  2. Correction: The Griffiths Autism Early Screening (GAES): A Novel Developmental Test for Screening Autism Spectrum Disorder
  3. Paroxysmal Dystonic Posturing Mimicking Nocturnal Leg Cramps as a Presenting Sign in an Infant with DCC Mutation, Callosal Agenesis and Mirror Movements
  4. Instrumented assessment of gait disturbance in PMM2-CDG adults: a feasibility analysis
  5. Genotype/Phenotype Relationship: Lessons From 137 Patients With PMM2‐CDG
  6. The Griffiths Autism Early Screening (GAES): A Novel Developmental Test for Screening Autism Spectrum Disorder
  7. Positive Impact of Home ERT for Mucopolysaccharidoses and Pompe Disease: The Lesson Learnt from the COVID-19 Pandemic
  8. Higher frequency of TMEM199-CDG in the southern mediterranean area is associated with c.92G>C (p.Arg31Pro) mutation
  9. Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample
  10. Copy Number Variations in Children with Tourette Syndrome: Systematic Investigation in a Clinical Setting
  11. PARK2 microdeletion in a multiplex family with autism spectrum disorder
  12. Early Sensory Profile in Autism Spectrum Disorders Predicts Emotional and Behavioral Issues
  13. Sensory Profiles in School-Aged Children with Autism Spectrum Disorder: A Descriptive Study Using the Sensory Processing Measure-2 (SPM-2)
  14. Defective IGF-1 prohormone N-glycosylation and reduced IGF-1 receptor signaling activation in congenital disorders of glycosylation
  15. Use of Nutritional Supplements Based on L-Theanine and Vitamin B6 in Children with Tourette Syndrome, with Anxiety Disorders: A Pilot Study
  16. COG6‐CDG : Novel variants and novel malformation
  17. Active site variants in STT3A cause a dominant type I congenital disorder of glycosylation with neuromusculoskeletal findings
  18. Diagnostic Approach to Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS): A Narrative Review of Literature Data
  19. Should patients with Phosphomannomutase 2-CDG (PMM2-CDG) be screened for adrenal insufficiency?
  20. N-Glycomics of Human Erythrocytes
  21. Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients
  22. Clinical, molecular and glycophenotype insights in SLC39A8-CDG
  23. N-Glycomics of Human Erythrocytes
  24. Psychometric Properties of the Italian Version of the Assessment of Identity Development in Adolescence (AIDA)
  25. Mitochondrial Fatty Acid β-Oxidation and Resveratrol Effect in Fibroblasts from Patients with Autism Spectrum Disorder
  26. Aberrant sialylation in a patient with a HNF1α variant and liver adenomatosis
  27. Clinical and radiological correlates of activities of daily living in cerebellar atrophy caused by PMM2 mutations (PMM2-CDG)
  28. A Novel Homozygous <b><i>ALG12</i></b> Mutation in a Patient with CDG Type Ig: New Report of a Case with a Mild Phenotype
  29. Incidence of Autism Spectrum Disorder in Youths Affected by Gilles de la Tourette Syndrome Based on Data from a Large Single Italian Clinical Cohort
  30. Self- and Parent-Reported Psychological Symptoms in Young Cancer Survivors and Control Peers: Results from a Clinical Center
  31. Epilepsy and movement disorders in CDG : Report on the oldest‐known MOGS‐CDG patient
  32. International consensus guidelines for phosphoglucomutase 1 deficiency ( PGM1‐CDG ): Diagnosis, follow‐up, and management
  33. HILIC-UPLC-MS for high throughput and isomeric N-glycan separation and characterization in Congenital Disorders Glycosylation and human diseases
  34. Potential Associations Among Alteration of Salivary miRNAs, Saliva Microbiome Structure, and Cognitive Impairments in Autistic Children
  35. COVID-19 Pandemic Outbreak and its Psychological Impact on Patients with Rare Lysosomal Diseases
  36. A new strategy implementing mass spectrometry in the diagnosis of congenital disorders of N-glycosylation (CDG)
  37. Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG
  38. Disentangling Restrictive and Repetitive Behaviors and Social Impairments in Children and Adolescents with Gilles de la Tourette Syndrome and Autism Spectrum Disorder
  39. Clinical correlates in children with autism spectrum disorder and CNVs: Systematic investigation in a clinical setting
  40. Aberrant Sialylation in a Patient with a <i>HNF1α</i> Variant and Liver Adenomatosis
  41. Metal and essential element levels in hair and association with autism severity
  42. ALG12-CDG: novel glycophenotype insights endorse the molecular defect
  43. Adjunct Diagnostic Value of Transcranial Magnetic Stimulation in Mucopolysaccharidosis-Related Cervical Myelopathy: A Pilot Study
  44. Diagnostic and Prognostic Value of Transcranial Magnetic Stimulation in Mucopolysaccharidosis-Related Cervical Myelopathy
  45. Hyperkinetic movement disorders in congenital disorders of glycosylation
  46. International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up
  47. SLC35A2‐CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals
  48. Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder
  49. Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study
  50. Online comprehension across different semantic categories in preschool children with autism spectrum disorder
  51. Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients
  52. CSF N-Glycoproteomics Using MALDI MS Techniques in Neurodegenerative Diseases
  53. International clinical guidelines for the management of phosphomannomutase 2‐congenital disorders of glycosylation: Diagnosis, treatment and follow up
  54. A Subset of Patients With Autism Spectrum Disorders Show a Distinctive Metabolic Profile by Dried Blood Spot Analyses
  55. Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
  56. Expanded Newborn Screening Using Tandem Mass Spectrometry: Seven Years of Experience in Eastern Sicily
  57. KARS-related diseases: progressive leukoencephalopathy with brainstem and spinal cord calcifications as new phenotype and a review of literature
  58. Study on the Role of Polymorphisms of the SOX-6 and MYB Genes and Fetal Hemoglobin Levels in Sicilian Patients with β-Thalassemia and Sickle Cell Disease
  59. CSF N-Glycomics Using MALDI MS Techniques in Alzheimer’s Disease
  60. Errata Corrige, Thalassemia Reports 2017; 7:6392
  61. Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder
  62. An Eye Tracker based Computer System to Support Oculomotor and Attention Deficit Investigations
  63. MALDI-MS profiling of serumO-glycosylation andN-glycosylation in COG5-CDG
  64. Granulocyte–Colony Stimulating Factor plus Plerixafor in Patients with β-thalassemia Major Results in the Effective Mobilization of Primitive CD34+ Cells with Specific Gene Expression Profile
  65. Familial 18q12.2 deletion supports the role of RNA-binding protein CELF4 in autism spectrum disorders
  66. Early-Onset Epileptic Encephalopathy in infants with different forms of Congenital Disorders of Glycosylation (CDG)
  67. Prominent neurological involvement in Dercum disease
  68. Unusual Neurological Presentation of Nevoid Basal Cell Carcinoma Syndrome (Gorlin-Goltz Syndrome)
  69. Response to Alpha-Interferon Treatment of the Congenital Dyserythropoietic Anemia type I in Two Sicilian Beta Thalassemia Carriers
  70. ALG1-CDG: Clinical and Molecular Characterization of 39 Unreported Patients
  71. New Codanin-1 Gene Mutations in a Italian Patient with Congenital Dyserythropoietic Anemia Type I and Heterozygous Beta-Thalassemia
  72. CSF N-glycoproteomics for early diagnosis in Alzheimer's disease
  73. Electroclinical features of a patient with GLUT1 deficiency syndrome and adult onset periodic weakness
  74. Congenital Dyserythropoietic Anemias: Molecular Diagnosis and Diagnostic Approach in a Cohort of Italian Patients
  75. Miglustat Does Not Prevent Neurological Involvement in Niemann Pick C Disease
  76. Defective CSF sialylation in autism spectrum disorders
  77. Optimizing the Molecular Diagnosis of GALNS: Novel Methods to Define and Characterize Morquio-A Syndrome-Associated Mutations
  78. Electroclinical Features of Early-Onset Epileptic Encephalopathies in Congenital Disorders of Glycosylation (CDGs)
  79. Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial
  80. Familial 1q22 microduplication associated with psychiatric disorders, intellectual disability and late-onset autoimmune inflammatory response
  81. A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation
  82. Development and Recent Progresses of Gene Therapy for β-Thalassemia
  83. Congenital Disorders of Glycosylation with Emphasis on Cerebellar Involvement
  84. Report of Two Never Treated Adult Sisters with Aromatic l-Amino Acid Decarboxylase Deficiency: A Portrait of the Natural History of the Disease or an Expanding Phenotype?
  85. First US Phase I Clinical Trial Of Globin Gene Transfer For The Treatment Of Beta-Thalassemia Major
  86. Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major
  87. Imaging findings of mucopolysaccharidoses: a pictorial review
  88. Serial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac death
  89. Phenotypic spectrum and prevalence of INPP5E mutations in Joubert Syndrome and related disorders
  90. Eye-tracking evaluation of ocular motility in Pompe disease
  91. Hurler disease (MPS IH): Evidence for the need of increased awareness by caring non-metabolic physicians
  92. DPM2-CDG: A muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy
  93. Glycomics of pediatric and adulthood diseases of the central nervous system
  94. An unknown cause of aortic valve stenosis: polycythemia vera
  95. Early Miglustat Therapy in Infantile Niemann-Pick Disease Type C
  96. Phenotypic heterogeneity in hereditary motor neuropathy type V: a new case report series
  97. Erythrocyte deformability evaluated by laser diffractometry in polycythemia vera
  98. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene
  99. Sporadic motor neuron disease in a familial novel SOD1 mutation: Incomplete penetrance or chance association?
  100. Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy
  101. The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation
  102. Krabbe leukodystrophy in a selected population with high rate of late onset forms: longer survival linked to c.121G>A (p.Gly41Ser) mutation
  103. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab
  104. Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study
  105. Secondary disorders of glycosylation in inborn errors of fructose metabolism
  106. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms
  107. Mucopolysaccharidosis VI: the Italian experience
  108. Mass spectrometry in the characterization of human genetic N‐glycosylation defects
  109. Multiplexed glycoproteomic analysis of glycosylation disorders by sequential yolk immunoglobulins immunoseparation and MALDI-TOF MS
  110. Clinical phenotype correlates to glycoprotein phenotype in a sib pair with CDG-Ia
  111. Inter- and intrafamilial variability in mucolipidosis II (I-cell disease)
  112. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease
  113. Chitotriosidase and Alzheimers Disease
  114. Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic involvement (intermediate phenotype)
  115. Intrathecal chitotriosidase and the outcome of multiple sclerosis
  116. Substrate reduction therapy in the infantile form of Tay-Sachs disease
  117. Callosal anomalies with interhemispheric cyst: Expanding the phenotype
  118. Congenital Insensitivity to Pain with Anhidrosis (NTRK1 Mutation) and Early Onset Renal Disease: Clinical Report on Three Sibs with a 25-Year Follow-Up in One of Them
  119. Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia
  120. Chitotriosidase activity in colostrum from African and Caucasian women
  121. Chitotriosidase in Patients with Acute Ischemic Stroke
  122. Human aldolase A natural mutants: relationship between flexibility of the C-terminal region and enzyme function
  123. Startle epilepsy complicating aspartylglucosaminuria
  124. A Novel Exon 1 Mutation in a Patient with Atypical Lafora Progressive Myoclonus Epilepsy Seen as Childhood‐onset Cognitive Deficit
  125. A 24-bp duplication in exon 10 of human chitotriosidase gene from the sub-Saharan to the Mediterranean area: role of parasitic diseases and environmental conditions
  126. Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers
  127. Dihydropyrimidine dehydrogenase deficiency and acute neurological presentation
  128. Plasma chitotriosidase activity in acute Plasmodium falciparum malaria
  129. Plasma chitotriosidase activity in patients with ?-thalassemia
  130. Plasma Chitotriosidase Activity in Acute Plasmodium falciparum Malaria
  131. Mutation analysis of the MECP2 gene in patients with Rett syndrome
  132. White matter changes mimicking a leukodystrophy in a patient with Mucopolysaccharidosis: characterization by MRI
  133. Bone ultrasonometry, bone density, and turnover markers in type 1 Gaucher disease
  134. Extraneurologic symptoms as presenting signs of Sanfilippo disease
  135. Plasma chitotriosidase activity in β-thalassemia major: a comparative study between Sicilian and Sardinian patients
  136. Plasma Chitotriosidase Activity Is a Marker of Recovery in Transplanted Patients Affected by β-Thalassemia major
  137. Arthrogryposis Multiplex Congenita and Pituitary Ectopia. A Case Report
  138. β-Hexosaminidase, α-d-mannosidase, and β-mannosidase expression in serum from patients with carbohydrate-deficient glycoprotein syndrome type I
  139. Tuberous breast deformity in an adolescent girl with Hurler-Scheie syndrome
  140. Carbohydrate-deficient glycoprotein syndromes: The Italian experience
  141. Haemostatic abnormalities and lupus anticoagulant activity in patients with Gaucher disease type I
  142. Extraordinary bone involvement in a Gaucher disease type I patient
  143. Clinical and Neuroradiological Follow-Up in Mucopolysaccharidosis Type III (Sanfilippo Syndrome)
  144. Peripheral lymphocyte subsets and other immune aspects in rett syndrome
  145. Point Mutations Throughout the GLI3 Gene Cause Greig Cephalopolysyndactyly Syndrome
  146. Rett Syndrome: Photographic Evidence of Rapid Regression
  147. Developmental patterns and neuropsychological assessment in patients with carbohydrate-deficient glycoconjugate syndrome type IA (phosphomannomutase deficiency)
  148. Plasma Chitotriosidase Activity in Patients with β-Thalassemia
  149. Lysosomal enzyme activities in serum and leukocytes from patients with carbohydrate-deficient glycoprotein syndrome type IA (phosphomannomutase deficiency)
  150. Phosphomannomutase deficiency is the main cause of carbohydrate-deficient glycoprotein syndrome with type I isoelectrofocusing pattern of serum sialotransferrins
  151. Two new mild homozygous mutations in Gaucher disease patients: Clinical signs and biochemical analyses
  152. Carbohydrate deficient glycoprotein (CDG) syndrome type I.
  153. Evidence for Genetic Heterogeneity in the Carbohydrate-Deficient Glycoprotein Syndrome Type I (CDG1)
  154. The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes
  155. Familial Dandy-Walker variant in CDG syndrome
  156. Haemostatic Studies in Carbohydrate-deficient Glycoprotein Syndrome Type I
  157. Olivopontocerebellar atrophy leading to recognition of carbohydrate-deficient glycoprotein syndrome type I
  158. Pancreatitis and organic acidemias
  159. Carbohydrate deficient glycoprotein syndrome type I: ophthalmic aspects in four Sicilian patients.